The article, titled “Safety, Tolerability and Immunogenicity of Vaccine ALZ-101 in Patients with Early Alzheimer’s Disease: Randomised, Controlled Trial”, presents the clinical results from the Company’s Phase 1b study of ALZ-101, a therapeutic vaccine candidate targeting toxic amyloid-beta oligomers. It includes an in-depth analysis of study data, covering both primary and secondary endpoints as well as a number of exploratory endpoints highlighting the potential disease-modifying effects of ALZ-101. The results demonstrate a favorable safety and tolerability profile along with the induction of a specific immune response, which collectively supports the continued clinical development of ALZ-101.

The publication provides external validation of the quality of the Company’s clinical data and strengthens the scientific foundation of ALZ-101 at a stage where Alzinova is actively preparing for the next phase of development. Visibility in an international scientific journal also contributes to increasing interest from the global research community and provides tangible support in the Company’s ongoing partnering discussions.

“Having our clinical results accepted for publication in a well-renowned scientific journal represents an important quality stamp for our clinical program and a clear validation of the strength of our technology. It strengthens our position in ongoing business discussions and supports our efforts to realize the commercial value of ALZ-101,” says Tord Labuda, CEO of Alzinova AB.

Supported by the positive clinical results, Alzinova is now intensifying preparations for the next stage of development. The Company is planning a Phase II study focused on further evaluating clinical efficacy, biomarkers, and dosing regimen in patients with early Alzheimer’s disease, with the ambition to initiate the study around the turn of the year. In parallel, dialogues with potential partners are ongoing ahead of the next phase of development.

The article will be published open access following the journal’s standard production process. The publication is expected to further increase the international visibility of ALZ-101 and serve as an important foundation for the Company’s continued clinical and business development.

About Alzheimer’s Research & Therapy
Alzheimer’s Research & Therapy is an international, fully open access journal focused on translational research in Alzheimer’s disease and other neurodegenerative disorders. The journal is published by BMC/Springer Nature and ranks in the top quality quartile globally within neuroscience (commonly referred to as Q1) based on citation metrics and other bibliometric rankings. It has a strong impact factor and five-year impact factor within its field, reflecting high scientific visibility and citation frequency.

For more information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com

About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com